BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29446481)

  • 41. Dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles.
    Albeitawi S; Marar EA; Reshoud FA; Hamadneh J; Hamza R; Alhasan G; Omeish H; Vigano P
    JBRA Assist Reprod; 2022 Jan; 26(1):28-32. PubMed ID: 34463444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?
    Orvieto R
    J Ovarian Res; 2015 Aug; 8():60. PubMed ID: 26293447
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols.
    Orvieto R; Rabinson J; Meltzer S; Zohav E; Anteby E; Homburg R
    Reprod Biomed Online; 2006 Aug; 13(2):198-201. PubMed ID: 16895632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin.
    Mills G; Dahan MH
    Arch Gynecol Obstet; 2022 Nov; 306(5):1731-1737. PubMed ID: 35932297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'.
    Ling LP; Phoon JW; Lau MS; Chan JK; Viardot-Foucault V; Tan TY; Nadarajah S; Tan HH
    Reprod Biomed Online; 2014 Sep; 29(3):392-4. PubMed ID: 25042608
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of GnRH agonist trigger with or without low-dose hCG on reproductive outcomes for PCOS women with freeze-all strategy: a propensity score matching study.
    Wang Q; Wan Q; Li T; Wang X; Hu Y; Zhong Z; Pu K; Ding Y; Tang X
    Arch Gynecol Obstet; 2024 Feb; 309(2):679-688. PubMed ID: 38032411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach.
    Fernández-Sánchez M; Fatemi H; García-Velasco JA; Heiser PW; Daftary GS; Mannaerts B
    Gynecol Endocrinol; 2023 Dec; 39(1):2205952. PubMed ID: 37156263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A decision-making algorithm for performing or cancelling embryo transfer in patients at high risk for ovarian hyperstimulation syndrome after triggering final oocyte maturation with hCG.
    Lainas GT; Lainas TG; Sfontouris IA; Venetis CA; Kyprianou MA; Petsas GK; Tarlatzis BC; Kolibianakis EM
    Hum Reprod Open; 2020; 2020(3):hoaa013. PubMed ID: 32529046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.
    Fatemi HM; Garcia-Velasco J
    Fertil Steril; 2015 Apr; 103(4):870-3. PubMed ID: 25724740
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study.
    Humaidan P
    Reprod Biomed Online; 2009 May; 18(5):630-4. PubMed ID: 19549440
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HCG trigger versus GnRH agonist trigger in PCOS patients undergoing IVF cycles: frozen embryo transfer outcomes.
    Deepika K; Suvarna R; Sumi M; Snehal D; Arveen V; Anuja K; Gautham P; Kamini R
    JBRA Assist Reprod; 2021 Feb; 25(1):48-58. PubMed ID: 32960521
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.
    Sousa M; Cunha M; Teixeira da Silva J; Oliveira C; Silva J; Viana P; Barros A
    Reprod Biol Endocrinol; 2015 Jun; 13():66. PubMed ID: 26100393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GnRHa to trigger final oocyte maturation: a time to reconsider.
    Humaidan P; Papanikolaou EG; Tarlatzis BC
    Hum Reprod; 2009 Oct; 24(10):2389-94. PubMed ID: 19608565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B; Tremellen K
    Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials.
    Humaidan P; Nelson SM; Devroey P; Coddington CC; Schwartz LB; Gordon K; Frattarelli JL; Tarlatzis BC; Fatemi HM; Lutjen P; Stegmann BJ
    Hum Reprod; 2016 Sep; 31(9):1997-2004. PubMed ID: 27343272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Larger oocyte cohorts maximize fresh IVF cycle birth rates and availability of surplus high-quality blastocysts for cryopreservation.
    Connell MT; Richter KS; Devine K; Hill MJ; DeCherney AH; Doyle JO; Tucker MJ; Levy MJ
    Reprod Biomed Online; 2019 May; 38(5):711-723. PubMed ID: 30922557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.